Infectious Disease

As cases approach the full-year 2025 total, declining vaccination coverage and vaccine hesitancy put pharmacists on the front lines of a public health crisis.

AAP challenges HHS as ACIP stalls, leaving pharmacists and health care in limbo on vaccine coverage and respiratory recommendations.

The first generic rifapentine expands affordable treatment for active and latent tuberculosis.

Retracted vaccine-autism study exposes statistical flaws, reigniting hepatitis B birth-dose debate and highlighting why pharmacists must rely on evidence-based data.

FDA clears first generic Xofluza tablet, bringing affordable single-dose flu treatment and prevention.

GSK and Spero Therapeutics’ newly approved carbapenem could be a standard of care in adults with complicated urinary tract infections who prefer oral administration.

How pharmacists differentiate respiratory diseases at the counter.

Phase 3 data show a once-weekly HIV pill maintains viral suppression like daily therapy, hinting at simpler long-acting care.

BA.3.2 variant spreads globally, testing vaccine matches as the FDA backs XFG immunizations.

Utah protocol streamlines large-volume immunoglobulin for measles-exposed infants as outbreaks surge.

Although currently contained outside of the US, the Bundibugyo strain of the virus reached an American worker in the Democratic Republic of Congo.

Oral ensitrelvir given within 72 hours cuts household symptomatic COVID-19 by 67%, showing safe postexposure prevention.

As health officials respond to ongoing concerns, Nathan Ott, PharmD, joined to discuss key hantavirus facts that pharmacists can relay to their communities.

By late February 2026, national data from the CDC reveal a test positivity rate of 9.1%, the highest recorded for the entire season at that point.

Despite WHO officials stating that risks from the outbreak remain low, experts are acting urgently to uncover details and provide support.

Local pharmacies deliver rapid flu, COVID-19, strep, and urinary tract infection tests with same-day treatment, easing access gaps and cutting urgent care costs.

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Pharmacists are taking the lead to combat misinformation on measles and preserve the nation’s fragile elimination status.

Phase 3 trials show once-daily bictegravir/lenacapavir keeps HIV suppressed after switching regimens, with strong safety and better satisfaction for complex-treatment patients.

HIV care faces challenges from persistent stigmas and misinformation, hindering effective prevention and treatment integration into primary health care.

With infectious disease rates expected to jump as US vaccine schedules are reworked, antimicrobial stewardship programs are seeking community pharmacists.

GSK announces promising phase 3 trial results for bepirovirsen, a potential treatment for chronic hepatitis B, showing significant functional cure rates.

The administration announces back-to-back approvals for oral therapies used to treat uncomplicated urogenital gonorrhea.

Antibiotics are a prominent medication class reserved for helping patients fight bacterial infections.